nach oben

Erschienen in:

30.04.2022 | Non-Thematic Review

Oncobiology and treatment of breast cancer in young women

verfasst von: Rakesh Kumar, Catarina Abreu, Masakazu Toi, Sunil Saini, Sandra Casimiro, Anshika Arora, Aswathy Mary Paul, Ravi Velaga, Pranela Rameshwar, Allan Lipton, Sudeep Gupta, Luis Costa

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Female breast cancer emerged as the leading cancer type in terms of incidence globally in 2020. Although mortality due to breast cancer has improved during the past three decades in many countries, this trend has reversed in women less than 40 years since the past decade. From the biological standpoint, there is consensus among experts regarding the clinically relevant definition of breast cancer in young women (BCYW), with an age cut-off of 40 years. The idea that breast cancer is an aging disease has apparently broken in the case of BCYW due to the young onset and an overall poor outcome of BCYW patients. In general, younger patients exhibit a worse prognosis than older pre- and postmenopausal patients due to the aggressive nature of cancer subtypes, a high percentage of cases with advanced stages at diagnosis, and a high risk of relapse and death in younger patients. Because of clinically and biologically unique features of BCYW, it is suspected to represent a distinct biologic entity. It is unclear why BCYW is more aggressive and has an inferior prognosis with factors that contribute to increased incidence. However, unique developmental features, adiposity and immune components of the mammary gland, hormonal interplay and crosstalk with growth factors, and a host of intrinsic and extrinsic risk factors and cellular regulatory interactions are considered to be the major contributing factors. In the present article, we discuss the status of BCYW oncobiology, therapeutic interventions and considerations, current limitations in fully understanding the basis and underlying cause(s) of BCYW, understudied areas of BCYW research, and postulated advances in the coming years for the field.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA, 71(3), 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Jr., Bianchi-Micheli, G., et al. (2020). ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of Oncology, 31(6), 674–696. https://doi.org/10.1016/j.annonc.2020.03.284CrossRefPubMed

Narod, S. A. (2012). Breast cancer in young women. Nature Review Clinical Oncology, 9(8), 460–470. https://doi.org/10.1038/nrclinonc.2012.102CrossRef

Daly, A. A., Rolph, R., Cutress, R. I., & Copson, E. R. (2021). A review of modifiable risk factors in young women for the prevention of breast cancer. Breast Cancer, 13, 241–257. https://doi.org/10.2147/BCTT.S268401CrossRefPubMedPubMedCentral

Hendrick, R. E., Helvie, M. A., & Monticciolo, D. L. (2021). Breast cancer mortality rates have stopped declining in US women younger than 40 Years. Radiology, 299(1), 143–149.CrossRef

Ghosh, J., Gupta, S., Desai, S., Shet, T., Radhakrishnan, S., Suryavanshi, P., … Badwe, R. A. (2011). Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian Journal of Cancer, 48(4), 391–396https://doi.org/10.4103/0019-509X.92245

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., et al. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173CrossRefPubMed

Bajpai, J., Ventrapati, P., Joshi, S., Wadasadawala, T., Rath, S., Pathak, R., et al. (2021). Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India. Breast (Edinburgh, Scotland), 60, 177–184. https://doi.org/10.1016/j.breast.2021.09.008CrossRef

Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer Statistics, 2017. CA, 67(1), 7–30.PubMed

10.

Breast cancer incidence (invasive) statistics | Cancer Research UK. (n.d.). Retrieved February 11, 2022, from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive#heading-One

11.

Okazaki, M., Bando, H., Tohno, E., Kujiraoka, Y., Iguchi-Manaka, A., Ichioka, E., … Hara, H. (2021). Investigation of the significance of population-based breast cancer screening among women aged under 40 years. Breast Cancer, 28(1), 75–81https://doi.org/10.1007/s12282-020-01131-x

12.

Nakata, K., Hiyama, E., Katanoda, K., Matsuda, T., Tada, Y., Inoue, M., et al. (2022). Cancer in adolescents and young adults in Japan: Epidemiology and cancer strategy. International Journal of Clinical Oncology, 27(1), 7–15. https://doi.org/10.1007/s10147-021-02064-xCrossRefPubMed

13.

Hayashi, N., Kumamaru, H., Isozumi, U., Aogi, K., Asaga, S., Iijima, K., et al. (2020). Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer (Tokyo, Japan), 27(5), 803–809. https://doi.org/10.1007/S12282-020-01139-3CrossRef

14.

Alvarez-Bañuelos, M. T., Segura-Jaramillo, K. A., Gómez-Rivera, E. D. C., Alarcón-Rojas, C. A., Morales-Romero, J., Sampieri, C. L., et al. (2021). Age under 30 years as a predictor of poor survival in a cohort of mexican women with breast cancer. Cancer Control, 28, 10732748211047408. https://doi.org/10.1177/10732748211047408CrossRefPubMedPubMedCentral

15.

Ntirenganya, F., Twagirumukiza, J. D., Bucyibaruta, G., Rugwizangoga, B., & Rulisa, S. (2021). Premenopausal breast cancer risk factors and associations with molecular subtypes: A case-control study. International Journal of Breast Cancer, 2021, 5560559. https://doi.org/10.1155/2021/5560559CrossRefPubMedPubMedCentral

16.

Chen, L.-J., Chang, Y.-J., & Chang, Y.-J. (2021). Treatment and long-term outcome of breast cancer in very young women: nationwide population-based study. BJS Open, 5(5). https://doi.org/10.1093/bjsopen/zrab087

17.

Conte, B., Soldato, D., Razeti, M. G., Fregatti, P., de Azambuja, E., Schettini, F., … Lambertini, M. (2022). De novo metastatic breast cancer arising in young women: review of the current evidence. Clinical Breast Cancer, 22(1), 78–87https://doi.org/10.1016/j.clbc.2021.10.001

18.

Szollár, A., Újhelyi, M., Polgár, C., Oláh, E., Pukancsik, D., Rubovszky, G., et al. (2019). A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36–45 years) breast cancer patients. European Journal of Surgical Oncology, 45(11), 2009–2015. https://doi.org/10.1016/j.ejso.2019.06.007CrossRefPubMed

19.

Suter, M. B., & Pagani, O. (2018). Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. Therapeutic Advances in Medical Oncology, 10, 1758835918776923. https://doi.org/10.1177/1758835918776923CrossRefPubMedPubMedCentral

20.

Azim, H. A. J., & Partridge, A. H. (2014). Biology of breast cancer in young women. Breast Cancer Research : BCR, 16(4), 427. https://doi.org/10.1186/s13058-014-0427-5CrossRefPubMedPubMedCentral

21.

Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA, 60(5), 277–300. https://doi.org/10.3322/caac.20073CrossRefPubMed

22.

Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y.-N., et al. (2008). Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. Journal of Clinical Oncology, 26(34), 5553–5560. https://doi.org/10.1200/JCO.2008.17.9705CrossRefPubMedPubMedCentral

23.

Zhong, W., Tan, L., Jiang, W. G., Chen, K., You, N., Sanders, A. J., et al. (2019). Effect of younger age on survival outcomes in T1N0M0 breast cancer: A propensity score matching analysis. Journal of Surgical Oncology, 119(8), 1039–1046. https://doi.org/10.1002/jso.25457CrossRefPubMed

24.

Copson, E., Eccles, B., Maishman, T., Gerty, S., Stanton, L., Cutress, R. I., et al. (2013). Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: The POSH study. Journal of the National Cancer Institute, 105(13), 978–988. https://doi.org/10.1093/jnci/djt134CrossRefPubMed

25.

Eccles, D., Gerty, S., Simmonds, P., Hammond, V., Ennis, S., & Altman, D. G. (2007). Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): Study protocol. BMC Cancer, 7, 160. https://doi.org/10.1186/1471-2407-7-160CrossRefPubMedPubMedCentral

26.

Melina Arnold, M., Morgan, E., O’Neill, C., Bardot, A., Walsh, P., Siesling, S., et al. (2021). From early to metastatic breast cancer: A systematic review and meta-analysis of distant recurrence rates. The Breast, 9, S61. https://doi.org/10.1016/S0960-9776(21)00576-2CrossRef

27.

Lima, S. M., Kehm, R. D., Swett, K., Gonsalves, L., & Terry, M. B. (2020). Trends in parity and breast cancer incidence in US women younger than 40 years from 1935 to 2015. JAMA Network Open, 3(3), e200929. https://doi.org/10.1001/jamanetworkopen.2020.0929CrossRefPubMedPubMedCentral

28.

MacMahon, B., Cole, P., Lin, T. M., Lowe, C. R., Mirra, A. P., Ravnihar, B., et al. (1970). Age at first birth and breast cancer risk. Bulletin of the World Health Organization, 43(2), 209–221.PubMedPubMedCentral

29.

Rosner, B., Colditz, G. A., & Willett, W. C. (1994). Reproductive risk factors in a prospective study of breast cancer: The Nurses’ health study. American Journal of Epidemiology, 139(8), 819–835. https://doi.org/10.1093/oxfordjournals.aje.a117079CrossRefPubMed

30.

Russo, J., Rivera, R., & Russo, I. H. (1992). Influence of age and parity on the development of the human breast. Breast Cancer Research and Treatment, 23(3), 211–218. https://doi.org/10.1007/BF01833517CrossRefPubMed

31.

Bonnier, P., Romain, S., Dilhuydy, J. M., Bonichon, F., Julien, J. P., Charpin, C., et al. (1997). Influence of pregnancy on the outcome of breast cancer: A case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. International Journal of Cancer, 72(5), 720–727. https://doi.org/10.1002/(sici)1097-0215(19970904)72:5<720::aid-ijc3>3.0.co;2-u

32.

Muenst, S., Mechera, R., Däster, S., Piscuoglio, S., Ng, C. K. Y., Meier-Abt, F., et al. (2017). Pregnancy at early age is associated with a reduction of progesterone-responsive cells and epithelial Wnt signaling in human breast tissue. Oncotarget, 8(14), 22353–22360. https://doi.org/10.18632/oncotarget.16023CrossRefPubMedPubMedCentral

33.

Brouckaert, O., Rudolph, A., Laenen, A., Keeman, R., Bolla, M. K., Wang, Q., et al. (2017). Reproductive profiles and risk of breast cancer subtypes: A multi-center case-only study. Breast Cancer Research, 19(1), 119. https://doi.org/10.1186/s13058-017-0909-3CrossRefPubMedPubMedCentral

34.

Nguyen, B., Venet, D., Lambertini, M., Desmedt, C., Salgado, R., Horlings, H. M., et al. (2019). Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. Breast Cancer Research, 21(1), 25. https://doi.org/10.1186/s13058-019-1111-6CrossRefPubMedPubMedCentral

35.

Asztalos, S., Gann, P. H., Hayes, M. K., Nonn, L., Beam, C. A., Dai, Y., et al. (2010). Gene expression patterns in the human breast after pregnancy. Cancer Prevention Research, 3(3), 301–311. https://doi.org/10.1158/1940-6207.CAPR-09-0069CrossRefPubMed

36.

Meier-Abt, F., Milani, E., Roloff, T., Brinkhaus, H., Duss, S., Meyer, D. S., et al. (2013). Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Research, 15(2), R36. https://doi.org/10.1186/bcr3419CrossRefPubMedPubMedCentral

37.

Russo, J., Balogh, G. A., & Russo, I. H. (2008). Full-term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiology, Biomarkers & Prevention, 17(1), 51–66. https://doi.org/10.1158/1055-9965.EPI-07-0678CrossRef

38.

Mauvais-Jarvis, P., Sitruk-Ware, R., & Kuttenn, F. (1982). Luteal phase defect and breast cancer genesis. Breast Cancer Research and Treatment, 2(2), 139–150. https://doi.org/10.1007/BF01806450CrossRefPubMed

39.

Atashgaran, V., Wrin, J., Barry, S. C., Dasari, P., & Ingman, W. V. (2016). Dissecting the biology of menstrual cycle-associated breast cancer risk. Frontier in Oncology, 6, 267. https://doi.org/10.3389/fonc.2016.00267CrossRef

40.

Ziegler, R. G., Fuhrman, B. J., Moore, S. C., & Matthews, C. E. (2015). Epidemiologic studies of estrogen metabolism and breast cancer. Steroids, 99(Pt A), 67–75. https://doi.org/10.1016/j.steroids.2015.02.015CrossRefPubMedPubMedCentral

41.

Apter, D., Reinilä, M., & Vihko, R. (1989). Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Can, 44(5), 783–787. https://doi.org/10.1002/ijc.2910440506CrossRef

42.

Russo, J., Tay, L. K., & Russo, I. H. (1982). Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Can Res and Treat, 2(1), 5–73. https://doi.org/10.1007/BF01805718CrossRef

43.

Emaus, A., Espetvedt, S., Veierød, M. B., Ballard-Barbash, R., Furberg, A.-S., Ellison, P. T., et al. (2008). 17-beta-estradiol in relation to age at menarche and adult obesity in premenopausal women. Human Rep, 23(4), 919–927. https://doi.org/10.1093/humrep/dem432CrossRef

44.

Emaus, A., Veierød, M. B., Furberg, A.-S., Espetvedt, S., Friedenreich, C., Ellison, P. T., et al. (2008). Physical activity, heart rate, metabolic profile, and estradiol in premenopausal women. Med and Sci in Sports and Exercise, 40(6), 1022–1030. https://doi.org/10.1249/MSS.0b013e318167411fCrossRef

45.

Jasienska, G., Ziomkiewicz, A., Lipson, S. F., Thune, I., & Ellison, P. T. (2006). High ponderal index at birth predicts high estradiol levels in adult women. American Journal of Human Biology, 18(1), 133–140. https://doi.org/10.1002/ajhb.20462CrossRefPubMed

46.

Finstad, S. E., Emaus, A., Potischman, N., Barrett, E., Furberg, A.-S., Ellison, P. T., et al. (2009). Influence of birth weight and adult body composition on 17beta-estradiol levels in young women. Cancer Causes & Control, 20(2), 233–242. https://doi.org/10.1007/s10552-008-9238-2CrossRef

47.

Furberg, A.-S., Jasienska, G., Bjurstam, N., Torjesen, P. A., Emaus, A., Lipson, S. F., … Thune, I. (2005). Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiology, Biomarkers & Prevention, 14(1), 33–40.

48.

Gómez-Flores-Ramos, L., Castro-Sánchez, A., Peña-Curiel, A., & Mohar-Betancourt, A. (2017). Molecular biology in young women with breast cancer: From tumor gene expression to DNA mutations. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 69(4), 181–192. https://doi.org/10.24875/ric.17002225CrossRefPubMed

49.

Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., et al. (2018). Germline BRCA mutation and outcome in young-onset breast cancer (POSH): A prospective cohort study. Lancet Onc, 19(2), 169–180. https://doi.org/10.1016/S1470-2045(17)30891-4CrossRef

50.

Kemp, Z., Turnbull, A., Yost, S., Seal, S., Mahamdallie, S., Poyastro-Pearson, E., et al. (2019). Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Network Open, 2(5), e194428. https://doi.org/10.1001/jamanetworkopen.2019.4428CrossRefPubMedPubMedCentral

51.

Terry, M. B., Michels, K. B., Brody, J. G., Byrne, C., Chen, S., Jerry, D. J., et al. (2019). Environmental exposures during windows of susceptibility for breast cancer: A framework for prevention research. Breast Can Res, 21(1), 96. https://doi.org/10.1186/s13058-019-1168-2CrossRef

52.

Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295(21), 2492–2502. https://doi.org/10.1001/jama.295.21.2492CrossRefPubMed

53.

Tao, L., Gomez, S. L., Keegan, T. H. M., Kurian, A. W., & Clarke, C. A. (2015). Breast cancer mortality in African-American and non-Hispanic White women by molecular subtype and satage at diagnosis: A population-based study. Cancer Epi Bio & Pre, 24(7), 1039–1045. https://doi.org/10.1158/1055-9965.EPI-15-0243CrossRef

54.

Lorona, N. C., Malone, K. E., & Li, C. I. (2021). Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. Breast Can Res and Treat, 190(3), 549–558. https://doi.org/10.1007/s10549-021-06311-7CrossRef

55.

Romieu, I. I., Amadou, A., & Chajes, V. (2017). The role of diet, physical activity, body fatness, and breastfeeding in breast cancer in young women: Epidemiological evidence. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 69(4), 193–203. https://doi.org/10.24875/ric.17002263CrossRefPubMed

56.

Mørch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., & Lidegaard, Ø. (2017). Contemporary hormonal contraception and the risk of breast cancer. New England J Med, 377(23), 2228–2239. https://doi.org/10.1056/NEJMoa1700732CrossRef

57.

Lonard, D. M., Kumar, R., & O’Malley, B. W. (2010). Minireview: The SRC family of coactivators: An entrée to understanding a subset of polygenic diseases? Molecular Endocrinology, 24, 279–285. https://doi.org/10.1210/me.2009-0276CrossRefPubMed

58.

Eswaran, J., Cyanam, D., Mudvari, P., Divijendra, S., Reddy, N., Pakala, S. B., et al. (2012). Transcriptomic landscape of breast cancers through mRNA sequencing. Science and Reports, 2, 264. https://doi.org/10.1038/srep00264CrossRef

59.

Shi, M., O’Brien, K. M., & Weinberg, C. R. (2020). Interactions between a polygenic risk score and non-genetic risk factors in young-onset breast cancer. Science and Reports, 10, 3242. https://doi.org/10.1038/s41598-020-60032-3CrossRef

60.

Yanes, T., Bettina Meiser, B., Kaur, R., Young, M.-A., Mitchell, P. B., Scheepers-Joynt, M., et al. (2021). Breast cancer polygenic risk scores: A 12-month prospective study of patient reported outcomes and risk management behavior. Genetics in Medicine, 23(12), 2316–2323. https://doi.org/10.1038/s41436-021-01288-6CrossRefPubMed

61.

Mars, N., Widén, E., Kerminen, S., Meretoja, T., Pirinen, M., Parolo, D. B., P., et al. (2020). The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nature Communications, 11(1), 6383. https://doi.org/10.1038/s41467-020-19966-5CrossRefPubMedPubMedCentral

62.

Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018). The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 19, 581–590. https://doi.org/10.1038/s41576-018-0018-xCrossRefPubMed

63.

Olsen, M., Fischer, K., Bossuyt, P. M., & Goetghebeur, E. (2021). Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification. BMC Cancer, 21(1), 1351. https://doi.org/10.1186/s12885-021-08937-8CrossRefPubMedPubMedCentral

64.

Sandiford, O. A., Donnelly, R. J., El-Far, M. H., Burgmeyer, L. M., Sinha, G., Pamarthi, S. H., et al. (2021). Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region. Cancer Research, 81(6), 1567–1582. https://doi.org/10.1158/0008-5472.CAN-20-2434CrossRefPubMed

65.

Bliss, S. A., Sinha, G., Sandiford, O. A., Williams, L. M., Engelberth, D. J., Guiro, K., et al. (2016). Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Research, 76(19), 5832–5844. https://doi.org/10.1158/0008-5472.CAN-16-1092CrossRefPubMed

66.

Moore, C. A., Ferrer, A. I., Alonso, S., Pamarthi, S. H., Sandiford, O. A., & Rameshwar, P. (2021). Exosomes in the healthy and malignant bone marrow microenvironment. Advances in Experimental Medicine and Biology, 1350, 67–89. https://doi.org/10.1007/978-3-030-83282-7_3CrossRefPubMed

67.

Hartkopf, A. D., Brucker, S. Y., Taran, F. A., Harbeck, N., von Au, A., Naume, B., et al. (2021). Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 154, 128–137. https://doi.org/10.1016/j.ejca.2021.06.028CrossRefPubMed

68.

Nassar, F. J., Chamandi, G., Tfaily, M. A., Zgheib, N. K., & Nasr, R. (2020). Peripheral blood-based biopsy for breast cancer risk prediction and early detection. Front Med (Lausanne), 7(28), 2020. https://doi.org/10.3389/fmed.2020.00028.eCollectionCrossRef

69.

Jordan, K. R., Hall, J. K., Schedin, T., Borakove, M., Xian, J. J., Dzieciatkowska, M., et al. (2020). Extracellular vesicles from young women’s breast cancer patients drive increased invasion of non-malignant cells via the focal adhesion kinase pathway: A proteomic approach. Breast Cancer Research, 22(1), 128. https://doi.org/10.1186/s13058-020-01363-xCrossRefPubMedPubMedCentral

70.

Bushnell, G. G., Deshmukh, A. P., den Hollander, P., Luo, M., Soundararajan, R., Jia, D., et al. (2021). Breast cancer dormancy: Need for clinically relevant models to address current gaps in knowledge. NPJ Breast Cancer, 7(1), 66. https://doi.org/10.1038/s41523-021-00269-xCrossRefPubMedPubMedCentral

71.

Patel, S. A., Ramkissoon, S. H., Bryan, M., Pliner, L. F., Dontu, G., Patel, P. S., et al. (2012). Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Science and Reports, 2, 906. https://doi.org/10.1038/srep00906CrossRef

72.

Greco, S. J., Ayer, S., Guiro, K., Sinha, G., Donnelly, R. J., El-Far, M. H., et al. (2021). Restoration of aged hematopoietic cells by their young counterparts through instructive microvesicles release. Aging (Albany NY), 13(21), 23981–24016. https://doi.org/10.18632/aging.203689CrossRef

73.

Kashiwagi, S., Yashiro, M., Takashima, T., Aomatsu, N., Kawajiri, H., Ogawa, Y., et al. (2013). c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. The British Journal of Surgery, 100(4), 490–496. https://doi.org/10.1002/bjs.9021CrossRefPubMed

74.

Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 15(8), 907–913. https://doi.org/10.1038/nm.2000CrossRefPubMed

75.

Smart, C. E., Wronski, A., French, J. D., Edwards, S. L., Asselin-Labat, M.-L., Waddell, N., et al. (2011). Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. Oncogene, 30(13), 1597–1607. https://doi.org/10.1038/onc.2010.538CrossRefPubMed

76.

McCredie, M. R. E., Dite, G. S., Southey, M. C., Venter, D. J., Giles, G. G., & Hopper, J. L. (2003). Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. British Journal of Cancer, 89(9), 1661–1663. https://doi.org/10.1038/sj.bjc.6601293CrossRefPubMedPubMedCentral

77.

Joshi, P. A., Jackson, H. W., Beristain, A. G., Di Grappa, M. A., Mote, P. A., Clarke, C. L., et al. (2010). Progesterone induces adult mammary stem cell expansion. Nature, 465(7299), 803–807. https://doi.org/10.1038/nature09091CrossRefPubMed

78.

Gonzalez-Suarez, E., Jacob, A. P., Jones, J., Miller, R., Roudier-Meyer, M. P., Erwert, R., et al. (2010). RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature, 468(7320), 103–107. https://doi.org/10.1038/nature09495CrossRefPubMed

79.

Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., … Penninger, J. M. (2010). Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature, 468(7320), 98–102https://doi.org/10.1038/nature09387

80.

Azim, H. A., Jr., Michiels, S., Bedard, P. L., Singhal, S. K., Criscitiello, C., Ignatiadis, M., et al. (2012). Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clinical Cancer Research, 18(5), 1341–1351. https://doi.org/10.1158/1078-0432.CCR-11-2599CrossRefPubMed

81.

Haynes, B. P., Viale, G., Galimberti, V., Rotmensz, N., Gibelli, B., Smith, I. E., & Dowsett, M. (2014). Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast cancer Research and Treatment, 148(2), 327–335. https://doi.org/10.1007/s10549-014-3181-6CrossRefPubMed

82.

Azim, H. A., Jr., Peccatori, F. A., Brohée, S., Branstetter, D., Loi, S., Viale, G., et al. (2015). RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Research, 17, 24. https://doi.org/10.1186/s13058-015-0538-7CrossRefPubMedPubMedCentral

83.

Van Poznak, C., Cross, S. S., Saggese, M., Hudis, C., Panageas, K. S., Norton, L., et al. (2006). Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. Journal of Clinical Pathology, 59(1), 56–63. https://doi.org/10.1136/jcp.2005.026534CrossRefPubMedPubMedCentral

84.

Sarink, D., Schock, H., Johnson, T., Overvad, K., Holm, H., Tjønneland, A., et al. (2017). Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: results from the EPIC cohort. Cancer Prevention Research (Philadelphia, Pa.), 10(9), 525–534. https://doi.org/10.1158/1940-6207.CAPR-17-0125CrossRef

85.

Gabrielson, M., Azam, S., Hardell, E., Holm, M., Ubhayasekera, K. A., Eriksson, M., … Hall, P. (2020). Hormonal determinants of mammographic density and density change. Breast Cancer Research, 22(1), 95https://doi.org/10.1186/s13058-020-01332-4

86.

Toriola, A. T., Appleton, C. M., Zong, X., Luo, J., Weilbaecher, K., Tamimi, R. M., & Colditz, G. A. (2018). Circulating receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and mammographic density in premenopausal women. Cancer Prevention Research (Philadelphia, Pa.), 11(12), 789–796. https://doi.org/10.1158/1940-6207.CAPR-18-0199CrossRef

87.

Toriola, A. T., Dang, H. X., Hagemann, I. S., Appleton, C. M., Colditz, G. A., Luo, J., & Maher, C. A. (2017). Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. Oncotarget, 8(43), 73787–73792. https://doi.org/10.18632/oncotarget.17909CrossRefPubMedPubMedCentral

88.

Olsson, H. L., & Olsson, M. L. (2020). The menstrual cycle and risk of breast cancer: A review. Frontiers in Oncology, 10, 21. https://doi.org/10.3389/fonc.2020.00021CrossRefPubMedPubMedCentral

89.

Duncan, W. C. (2021). The inadequate corpus luteum. Reproduction & fertility, 2(1), C1–C7. https://doi.org/10.1530/RAF-20-0044CrossRef

90.

Brisken, C., Hess, K., & Jeitziner, R. (2015). Progesterone and overlooked endocrine pathways in breast cancer pathogenesis. Endocrinology, 156(10), 3442–3450. https://doi.org/10.1210/en.2015-1392CrossRefPubMedPubMedCentral

91.

Wilson, C., Brown, H., & Holen, I. (2016). The endocrine influence on the bone microenvironment in early breast cancer. Endocrine Related Cancer, 23(12), R567–R576. https://doi.org/10.1530/ERC-16-0238CrossRefPubMed

92.

Pardo, I., Lillemoe, H. A., Blosser, R. J., Choi, M., Sauder, C. A. M., Doxey, D. K., & a;. (2014). Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. Breast Cancer Research, 16(2), R26. https://doi.org/10.1186/bcr3627CrossRefPubMedPubMedCentral

93.

Savolainen-Peltonen, H., Vihma, V., Wang, F., Turpeinen, U., Hämäläinen, E., Haanpää, M., et al. (2018). Estrogen biosynthesis in breast adipose tissue during menstrual cycle in women with and without breast cancer. Gynecological Endocrinology, 34(12), 1039–1043. https://doi.org/10.1080/09513590.2018.1474868CrossRefPubMed

94.

Hetemäki, N., Mikkola, T. S., Tikkanen, M. J., Wang, F., Hämäläinen, E., Turpeinen, U., et al. (2021). Adipose tissue estrogen production and metabolism in premenopausal women. J of Steroid Bio and Mol Bio, 209, 105849. https://doi.org/10.1016/j.jsbmb.2021.105849CrossRef

95.

Zhang, Y., Nadeau, M., Faucher, F., Lescelleur, O., Biron, S., Daris, M., et al. (2009). Progesterone metabolism in adipose cells. Mol and Cell End, 298(1–2), 76–83. https://doi.org/10.1016/j.mce.2008.09.034CrossRef

96.

Kershaw, E. E., & Flier, J. S. (2004). Adipose tissue as an endocrine organ. J Cli Endo and Met, 89(6), 2548–2556. https://doi.org/10.1210/jc.2004-0395CrossRef

97.

Wiebe, J. P., Muzia, D., Hu, J., Szwajcer, D., Hill, S. A., & Seachrist, J. L. (2000). The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Research, 60(4), 936–943.PubMed

98.

Lee, W., Wang, Z., Saffern, M., Jun, T., & Huang, K.-L. (2021). Genomic and molecular features distinguish young adult cancer from later-onset cancer. Cell Reports, 37(7), 110005. https://doi.org/10.1016/j.celrep.2021.110005CrossRefPubMed

99.

Callihan, E. B., Gao, D., Jindal, S., Lyons, T. R., Manthey, E., Edgerton, S., et al. (2013). Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Can Res & Treat, 138(2), 549–559. https://doi.org/10.1007/s10549-013-2437-xCrossRef

100.

Goddard, E. T., Bassale, S., Schedin, T., Jindal, S., Johnston, J., Cabral, E., et al. (2019). Association between postpartum breast cancer diagnosis and metastasis and the clinical features underlying risk. JAMA Network Open, 2(1), e186997. https://doi.org/10.1001/jamanetworkopen.2018.6997CrossRefPubMedPubMedCentral

101.

Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., et al. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: Results from an international collaborative study. J Cli Onc, 31(20), 2532–2539. https://doi.org/10.1200/JCO.2012.45.6335CrossRef

102.

Johansson, A. L. V., Andersson, T.M.-L., Hsieh, C.-C., Cnattingius, S., & Lambe, M. (2011). Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiology, Biomarkers & Prevention, 20(9), 1865–1872. https://doi.org/10.1158/1055-9965.EPI-11-0515CrossRef

103.

Hartman, E. K., & Eslick, G. D. (2016). The prognosis of women diagnosed with breast cancer before, during and after pregnancy: A meta-analysis. Breast Can Res and Treat, 160(2), 347–360. https://doi.org/10.1007/s10549-016-3989-3CrossRef

104.

Lyons, T. R., O’Brien, J., Borges, V. F., Conklin, M. W., Keely, P. J., Eliceiri, K. W., … Schedin, P. (2011). Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature Med, 17(9), 1109–1115https://doi.org/10.1038/nm.2416

105.

McDaniel, S. M., Rumer, K. K., Biroc, S. L., Metz, R. P., Singh, M., Porter, W., & Schedin, P. (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Path, 168(2), 608–620. https://doi.org/10.2353/ajpath.2006.050677CrossRefPubMedPubMedCentral

106.

Martinson, H. A., Jindal, S., Durand-Rougely, C., Borges, V. F., & Schedin, P. (2015). Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Can, 136(8), 1803–1813. https://doi.org/10.1002/ijc.29181CrossRef

107.

Watson, C. J., & Kreuzaler, P. A. (2011). Remodeling mechanisms of the mammary gland during involution. Int J Dev Bio, 55(7–9), 757–762. https://doi.org/10.1387/ijdb.113414cwCrossRef

108.

Lindahl, G., Rzepecka, A., & Dabrosin, C. (2019). Increased extracellular osteopontin levels in normal human breast tissue at high risk of developing cancer and its association with inflammatory biomarkers in situ. Frontiers in Oncology, 9, 746. https://doi.org/10.3389/fonc.2019.00746CrossRefPubMedPubMedCentral

109.

Ferguson, J. E., Schor, A. M., Howell, A., & Ferguson, M. W. (1992). Changes in the extracellular matrix of the normal human breast during the menstrual cycle. Cell and Tissue Res, 268(1), 167–177. https://doi.org/10.1007/BF00338066CrossRef

110.

Lu, P., Weaver, V. M., & Werb, Z. (2012). The extracellular matrix: A dynamic niche in cancer progression. Journal of Cell Bio, 196(4), 395–406. https://doi.org/10.1083/jcb.201102147CrossRef

111.

Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867. https://doi.org/10.1038/nature01322CrossRefPubMedPubMedCentral

112.

Guo, Q., Minnier, J., Burchard, J., Chiotti, K., Spellman, P., & Schedin, P. (2017). Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight, 2(6), e89206. https://doi.org/10.1172/jci.insight.89206CrossRefPubMedPubMedCentral

113.

Körner, A., Bernard, A., Fitzgerald, J. C., Alarcon-Barrera, J. C., Kostidis, S., Kaussen, T., … Mirakaj, V. (2021). Sema7A is crucial for resolution of severe inflammation. Proceedings of the National Academy of Sciences of the United States of America, 118(9). https://doi.org/10.1073/pnas.2017527118

114.

Tarullo, S. E., Hill, R. C., Hansen, K. C., Behbod, F., Borges, V. F., Nelson, A. C., & Lyons, T. R. (2020). Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival. Oncogene, 39(13), 2772–2785. https://doi.org/10.1038/s41388-020-1192-9CrossRefPubMedPubMedCentral

115.

Borges, V. F., Hu, J., Young, C., Maggard, J., Parris, H. J., Gao, D., & Lyons, T. R. (2020). Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer. NPJ Breast Can. https://doi.org/10.1038/s41523-020-00198-1CrossRef

116.

Crump, L. S., Wyatt, G. L., Rutherford, T. R., Richer, J. K., Porter, W. W., & Lyons, T. R. (2021). Hormonal regulation of semaphorin 7a in ER(+) breast cancer drives therapeutic resistance. Cancer Research, 81(1), 187–198. https://doi.org/10.1158/0008-5472.CAN-20-1601CrossRefPubMed

117.

Park, C., Yoon, K.-A., Kim, J., Park, I. H., Park, S. J., Kim, M. K., et al. (2019). Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women. Cancer Science, 110(5), 1760–1770. https://doi.org/10.1111/cas.13982CrossRefPubMedPubMedCentral

118.

Yau, C., Fedele, V., Roydasgupta, R., Fridlyand, J., Hubbard, A., Gray, J. W., et al. (2007). Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Research, 9(5), R59. https://doi.org/10.1186/bcr1765CrossRefPubMedPubMedCentral

119.

Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology, 26(20), 3324–3330. https://doi.org/10.1200/JCO.2007.14.2471CrossRefPubMed

120.

Azim, H. A., Jr., Nguyen, B., Brohée, S., Zoppoli, G., & Sotiriou, C. (2015). Genomic aberrations in young and elderly breast cancer patients. BMC Medicine, 13, 266. https://doi.org/10.1186/s12916-015-0504-3CrossRefPubMedPubMedCentral

121.

Waks, A. G., Kim, D., Jain, E., Snow, C., Kirkner, G. J., Rosenberg, S. M., et al. (2022). Somatic and germline genomic alterations in very young women with breast cancer. Clinical Can Res. https://doi.org/10.1158/1078-0432.CCR-21-2572CrossRef

122.

Gu, X., Wang, B., Zhu, H., Zhou, Y., Horning, A. M., Huang, T.H.-M., et al. (2020). Age-associated genes in human mammary gland drive human breast cancer progression. Breast Can Res, 22(1), 64. https://doi.org/10.1186/s13058-020-01299-2CrossRef

123.

Colak, D., Nofal, A., Albakheet, A., Nirmal, M., Jeprel, H., Eldali, A., et al. (2013). Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS ONE, 8(5), e63204. https://doi.org/10.1371/journal.pone.0063204CrossRefPubMedPubMedCentral

124.

Kan, Z., Ding, Y., Kim, J., Jung, H. H., Chung, W., Lal, S., et al. (2018). Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 9(1), 1725. https://doi.org/10.1038/s41467-018-04129-4CrossRefPubMedPubMedCentral

125.

Jindal, S., Pennock, N. D., Sun, D., Horton, W., Ozaki, M. K., Narasimhan, J., et al. (2021). Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nature Communications, 12(1), 6341. https://doi.org/10.1038/s41467-021-26505-3CrossRefPubMedPubMedCentral

126.

Pirone, J. R., D’Arcy, M., Stewart, D. A., Hines, W. C., Johnson, M., Gould, M. N., et al. (2012). Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 21(10), 1735–1744. https://doi.org/10.1158/1055-9965.EPI-12-0451CrossRef

127.

Wang, J., Peng, C., Guranich, C., Heng, Y. J., Baker, G. M., Rubadue, C. A., et al. (2021). Early-life body adiposity and the breast tumor transcriptome. Journal of the National Cancer Institute, 113(6), 778–784. https://doi.org/10.1093/jnci/djaa169CrossRefPubMed

128.

Kang, T., Yau, C., Wong, C. K., Sanborn, J. Z., Newton, Y., Vaske, C., et al. (2020). A risk-associated active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Research : BCR, 22(1), 81. https://doi.org/10.1186/s13058-020-01322-6CrossRefPubMedPubMedCentral

129.

Osako, T., Lee, H., Turashvili, G., Chiu, D., McKinney, S., Joosten, S. E. P., et al. (2020). Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects. Nature Cancer, 1(5), 518–532. https://doi.org/10.1038/s43018-020-0060-4CrossRefPubMed

130.

Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D., & Smith, H. S. (1996). Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (New York, N.Y.), 274(5295), 2057–2059. https://doi.org/10.1126/science.274.5295.2057CrossRef

131.

Evans, A., Trimboli, R. M., Athanasiou, A., Balleyguier, C., Baltzer, P. A., Bick, U., et al. (2018). Breast ultrasound: Recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights into Imaging, 9(4), 449–461. https://doi.org/10.1007/s13244-018-0636-zCrossRefPubMedPubMedCentral

132.

Denduluri, N., Somerfield, M. R., Chavez-MacGregor, M., Comander, A. H., Dayao, Z., Eisen, A., … Giordano, S. H. (2021). Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. Journal of Clinical Oncology, 39(6), 685–693https://doi.org/10.1200/JCO.20.02510

133.

Chaudhary, L. N. (2021). Clinical and psychosocial challenges of breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncology Practice, 17(6), 317–319. https://doi.org/10.1200/OP.21.00111CrossRefPubMedPubMedCentral

134.

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., et al. (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine, 379(2), 111–121. https://doi.org/10.1056/NEJMoa1804710CrossRefPubMed

135.

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., et al. (2019). Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. New England journal of medicine, 380(25), 2395–2405. https://doi.org/10.1056/NEJMoa1904819CrossRefPubMed

136.

Piccart, M., van ’t Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J. Y., et al. (2021). 70-gene signature as an aid for treatment decisions in early breast cancer: Updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncology, 22(4), 476–488. https://doi.org/10.1016/S1470-2045(21)00007-3CrossRefPubMed

137.

Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., et al. (2021). 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. New England Journal of Medicine, 385(25), 2336–2347. https://doi.org/10.1056/NEJMoa2108873CrossRefPubMed

138.

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810–821. https://doi.org/10.1056/NEJMoa1910549CrossRefPubMed

139.

Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., et al. (2017). Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncology, 3(10), 1378–1385. https://doi.org/10.1001/jamaoncol.2017.1007CrossRefPubMedPubMedCentral

140.

Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., et al. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603. Journal of Clinical Oncology, 33(1), 13–21. https://doi.org/10.1200/JCO.2014.57.0572CrossRefPubMed

141.

Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chem... | OncologyPRO. (n.d.). Retrieved February 11, 2022, from https://oncologypro.esmo.org/meeting-resources/esmo-congress/event-free-survival-efs-overall-survival-os-and-safety-of-adding-veliparib-v-plus-carboplatin-cb-or-carboplatin-alone-to-neoadjuvant-chem

142.

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., et al. (2021). Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. Journal of Clinical Oncology, 39(13), 1448–1457. https://doi.org/10.1200/JCO.20.01204CrossRefPubMed

143.

von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., et al. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. New England Journal of Medicine, 380(7), 617–628. https://doi.org/10.1056/NEJMoa1814017CrossRef

144.

Gulia, S., Kannan, S., Badwe, R., & Gupta, S. (2020). Evaluation of 1-year vs shorter durations of adjuvant trastuzumab among patients with early breast cancer: An individual participant data and trial-level meta-analysis. JAMA Network Open, 3(8), e2011777. https://doi.org/10.1001/jamanetworkopen.2020.11777CrossRefPubMedPubMedCentral

145.

Cathcart-Rake, E. J., Ruddy, K. J., Bleyer, A., & Johnson, R. H. (2021). Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncology Practice, 17(6), 305–313. https://doi.org/10.1200/OP.20.00793CrossRefPubMed

146.

Lu, Y.-S., Wong, A., Kim, H.-J. (2021). Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in premenopausal women. Front. Oncol., Article 700722. https://doi.org/10.3389/fonc.2021.700722

147.

Partridge, A. H. (2013). Cancer survivorship and the young breast cancer patient: Addressing the important issues. The Oncologist, 18(8), e19-20. https://doi.org/10.1634/theoncologist.2013-0300CrossRefPubMedPubMedCentral

148.

Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., … Lindor, N. M. (2015). American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 33(31), 3660–3667https://doi.org/10.1200/JCO.2015.63.0996

149.

Moore, H. C. F., Unger, J. M., Phillips, K.-A., Boyle, F., Hitre, E., Moseley, A., et al. (2019). Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. Journal of the National Cancer Institute, 111(2), 210–213. https://doi.org/10.1093/jnci/djy185CrossRefPubMed

150.

Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., et al. (2015). Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA, 314(24), 2632–2640. https://doi.org/10.1001/jama.2015.17291CrossRefPubMed

151.

Leonard, R. C. F., Adamson, D. J. A., Bertelli, G., Mansi, J., Yellowlees, A., Dunlop, J., et al. (2017). GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Annals of Oncology, 28(8), 1811–1816. https://doi.org/10.1093/annonc/mdx184CrossRefPubMed

152.

Lambertini, M., Blondeaux, E., Bruzzone, M., Perachino, M., Anderson, R. A., de Azambuja, E., et al. (2021). Pregnancy sfter breast cancer: A systematic review and meta-Analysis. Journal of Clinical Oncology, 39(29), 3293–3305. https://doi.org/10.1200/JCO.21.00535CrossRefPubMed

153.

Lambertini, M., Ameye, L., Hamy, A.-S., Zingarello, A., Poorvu, P. D., Carrasco, E., et al. (2020). Pregnancy after breast cancer in patients with germline BRCA mutations. Journal of Clinical Oncology, 38(26), 3012–3023. https://doi.org/10.1200/JCO.19.02399CrossRefPubMed

154.

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., et al. (2016). Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. Journal of Clinical Oncology, 2016(34), 2221–2231. https://doi.org/10.1200/JCO.2015.64.3171CrossRef

155.

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., et al. (2018). Tailoring adjuvant endocrine therapy for premenopausal breast cancer. New England Journal of Medicine, 379(2), 122–137. https://doi.org/10.1056/NEJMoa1803164CrossRefPubMed

156.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials. The lancet Oncology. https://doi.org/10.1016/S1470-2045(21)00758-0CrossRef

157.

Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., et al. (2020). Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial. The lancet Oncology, 21, 60–72. https://doi.org/10.1016/S1470-2045(19)30687-4CrossRefPubMed

158.

Francesco Perrone, F., Laurentiis, M. D., De Placido, S., Orditura, M., Cinieri, S., Riccardi, F., et al. (2019). Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer. The HOBOE phase 3 randomised trial. European Journal of Cancer, 118, 178–186. https://doi.org/10.1016/j.ejca.2019.05.004CrossRefPubMed

159.

Arlindo, R., Ferreira, J. R., Miranda, A., Mayer, A., Passos-Coelho, J. L., Brito, M., et al. (2019). Effectiveness of adjuvant ovarian function suppression in premenopausal women with early breast cancer: A multicenter cohort study. Clinical Breast Cancer, 19(5), 654–667. https://doi.org/10.1016/j.clbc.2019.06.003CrossRef

160.

Early Breast Cancer Trialists’ Collaborative G. (2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet, 386, 1353–1361. https://doi.org/10.1016/S0140-6736(15)60908-4CrossRef

161.

Coleman, R., Hall, A., Albanell, J., Hanby, A., Bell, R., Cameron, D., et al. (2017). Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: A secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The lancet Oncology, 18, 1543–1552. https://doi.org/10.1016/S1470-2045(17)30603-4CrossRefPubMed

162.

Vila, J., Gandini, S., & Gentilini, O. (2015). Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast (Edinburgh, Scotland), 24(3), 175–181. https://doi.org/10.1016/j.breast.2015.02.002CrossRef

163.

Tolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., et al. (2019). Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology, 37(22), 1868–1875. https://doi.org/10.1200/JCO.19.00066CrossRefPubMedPubMedCentral

164.

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., et al. (2019). Overall survival with ribociclib plus endocrine therapy in breast cancer. New England Journal of Medicine, 381(4), 307–316. https://doi.org/10.1056/NEJMoa1903765CrossRefPubMed

Titel: Oncobiology and treatment of breast cancer in young women
verfasst von: Rakesh Kumar
Catarina Abreu
Masakazu Toi
Sunil Saini
Sandra Casimiro
Anshika Arora
Aswathy Mary Paul
Ravi Velaga
Pranela Rameshwar
Allan Lipton
Sudeep Gupta
Luis Costa
Publikationsdatum: 30.04.2022
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2022
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10034-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Oncobiology and treatment of breast cancer in young women

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Obesity, cancer risk, and time-restricted eating

The obesity-breast cancer link: a multidisciplinary perspective

The role of bone marrow adipocytes in cancer progression: the impact of obesity

Breast cancer microenvironment and obesity: challenges for therapy

Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment

The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie